The epidemiology and clinical implications of genetic variation in prostate cancer

Urologic Clinics of North America

Volumn 41, Issue 2, 2014, Pages 277-297

  Helfand, Brian T ^a   Catalona, William J ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Genetic variants; Prostate cancer; Susceptibility; Tumor aggressiveness

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ALLELE; CANCER RISK; CANCER SCREENING; COPY NUMBER VARIATION; DIAGNOSTIC TEST; GENE EXPRESSION; GENE MUTATION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC VARIANTS; PROSTATE CANCER; SUSCEPTIBILITY; TUMOR AGGRESSIVENESS;

DNA, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MORBIDITY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH;

EID: 84898467329     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2014.01.001     Document Type: Review

References (230)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
2. Shin H.R., Masuyer E., Ferlay J., et al. Cancer in Asia-incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev 2010, 11(Suppl 2):11-16.
3. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
4. Bartsch G., Horninger W., Klocker H., et al. Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008, 101(7):809-816.
5. Desireddi N.V., Roehl K.A., Loeb S., et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007, 70(5):950-955.
6. Amling C.L. Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening?. Curr Treat Options Oncol 2006, 7(5):337-345.
7. Trinchieri A., Moretti R. Trends in prostate cancer epidemiology in the year 2000. Arch Ital Urol Androl 2005, 77(3):164-166.
8. Loeb S., Catalona W.J. Prostate-specific antigen screening: pro. Curr Opin Urol 2010, 20(3):185-188.
9. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358(12):1250-1261.
10. Wilt T.J., Brawer M.K., Jones K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367(3):203-213.
11. Ficarra V., Novara G., Rosen R.C., et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012, 62(3):405-417.
12. Carter B.S., Beaty T.H., Steinberg G.D., et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992, 89(8):3367-3371.
13. Eeles R.A. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 1999, 2(1):9-15.
14. Edwards S.M., Eeles R.A. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 2004, 129C(1):65-73.
15. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343(2):78-85.
16. Gronberg H., Wiklund F., Damber J.E. Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations. Cancer 1999, 86(3):477-483.
17. Zeegers M.P., Jellema A., Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003, 97(8):1894-1903.
18. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002, 168(3):906-913.
19. Zuhlke K.A., Johnson A.M., Okoth L.A., et al. Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. Fam Cancer 2012, 11(4):595-600.
20. Isaacs W.B. Inherited susceptibility for aggressive prostate cancer. Asian J Androl 2012, 14(3):415-418.
21. Catalona W.J., Bailey-Wilson J.E., Camp N.J., et al. National Cancer Institute prostate cancer genetics workshop. Cancer Res 2011, 71(10):3442-3446.
22. Choudhury A.D., Eeles R., Freedland S.J., et al. The role of genetic markers in the management of prostate cancer. Eur Urol 2012, 62(4):577-587.
23. Schaid D.J. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004, 13(Spec No 1):R103-R121.
24. Xu J., Dimitrov L., Chang B.L., et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005, 77(2):219-229.
25. The Breast Cancer Linkage Consortium Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91(15):1310-1316.
26. Castro E., Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 2012, 14(3):409-414.
27. Bancroft E.K., Page E.C., Castro E., et al. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. Eur Urol 2014, [Epub ahead of Print].
28. Sundararajan S., Ahmed A., Goodman O.B. The relevance of BRCA genetics to prostate cancer pathogenesis and treatment. Clin Adv Hematol Oncol 2011, 9(10):748-755.
29. Gudmundsdottir K., Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25(43):5864-5874.
30. Boulton S.J. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006, 34(Pt 5):633-645.
31. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4(10):814-819.
32. Agalliu I., Karlins E., Kwon E.M., et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007, 97(6):826-831.
33. Kote-Jarai Z., Leongamornlert D., Saunders E., et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011, 105(8):1230-1234.
34. Whittemore A.S., Gong G., Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997, 60(3):496-504.
35. Risch H.A., McLaughlin J.R., Cole D.E., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006, 98(23):1694-1706.
36. Roa B.B., Boyd A.A., Volcik K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14(2):185-187.
37. Oddoux C., Struewing J.P., Clayton C.M., et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996, 14(2):188-190.
38. Vazina A., Baniel J., Yaacobi Y., et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 2000, 83(4):463-466.
39. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336(20):1401-1408.
40. Tryggvadottir L., Vidarsdottir L., Thorgeirsson T., et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007, 99(12):929-935.
41. Thorne H., Willems A.J., Niedermayr E., et al. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 2011, 4(7):1002-1010.
42. Edwards S.M., Evans D.G., Hope Q., et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010, 103(6):918-924.
43. Narod S.A., Neuhausen S., Vichodez G., et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008, 99(2):371-374.
44. Gallagher D.J., Gaudet M.M., Pal P., et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010, 16(7):2115-2121.
45. Yang D., Khan S., Sun Y., et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011, 306(14):1557-1565.
46. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
47. Fong P.C., Yap T.A., Boss D.S., et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28(15):2512-2519.
48. Gallagher D.J., Cronin A.M., Milowsky M.I., et al. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int 2012, 109(5):713-719.
49. Stoffel E., Mukherjee B., Raymond V.M., et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009, 137(5):1621-1627.
50. Aarnio M., Mecklin J.P., Aaltonen L.A., et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995, 64(6):430-433.
51. Raymond V.M., Mukherjee B., Wang F., et al. Elevated risk of prostate cancer among men with lynch syndrome. J Clin Oncol 2013, 31(14):1713-1718.
52. Bauer C.M., Ray A.M., Halstead-Nussloch B.A., et al. Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 2011, 10(1):37-42.
53. da Silva F.C., de Oliveira L.P., Santos E.M., et al. Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer 2010, 9(4):563-570.
54. Goecke T., Schulmann K., Engel C., et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 2006, 24(26):4285-4292.
55. Scott R.J., McPhillips M., Meldrum C.J., et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 2001, 68(1):118-127.
56. Kruglyak L., Nickerson D.A. Variation is the spice of life. Nat Genet 2001, 27(3):234-236.
57. Marian A.J. Molecular genetic studies of complex phenotypes. Transl Res 2012, 159(2):64-79.
58. Verma R.S., Manikal M., Conte R.A., et al. Chromosomal basis of adenocarcinoma of the prostate. Cancer Invest 1999, 17(6):441-447.
59. Bova G.S., Isaacs W.B. Review of allelic loss and gain in prostate cancer. World J Urol 1996, 14(5):338-346.
60. Freedman M.L., Haiman C.A., Patterson N., et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006, 103(38):14068-14073.
61. Amundadottir L.T., Sulem P., Gudmundsson J., et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006, 38(6):652-658.
62. Al Olama A.A., Kote-Jarai Z., Giles G.G., et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009, 41(10):1058-1060.
63. Gudmundsson J., Sulem P., Gudbjartsson D.F., et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet 2012, 44(12):1326-1329.
64. Robbins C., Torres J.B., Hooker S., et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res 2007, 17(12):1717-1722.
65. Ellwood-Yen K., Graeber T.G., Wongvipat J., et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4(3):223-238.
66. Yeager M., Orr N., Hayes R.B., et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007, 39(5):645-649.
67. Jia L., Landan G., Pomerantz M., et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet 2009, 5(8):e1000597.
68. Ahmadiyeh N., Pomerantz M.M., Grisanzio C., et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A 2010, 107(21):9742-9746.
69. Pomerantz M.M., Beckwith C.A., Regan M.M., et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 2009, 69(13):5568-5574.
70. Tuupanen S., Turunen M., Lehtonen R., et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009, 41(8):885-890.
71. Meyer K.B., Maia A.T., O'Reilly M., et al. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet 2011, 7(7):e1002165.
72. Eeles R.A., Olama A.A., Benlloch S., et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013, 45(4):385-391. 391.e1-2.
73. Kote-Jarai Z., Saunders E.J., Leongamornlert D.A., et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013, 22(12):2520-2528.
74. Foulkes W.D. Inherited susceptibility to common cancers. N Engl J Med 2008, 359(20):2143-2153.
75. Kader A.K., Sun J., Isaacs S.D., et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009, 69(11):1195-1205.
76. Wiklund F.E., Adami H.O., Zheng S.L., et al. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 2009, 18(5):1659-1662.
77. Sun J., Chang B.L., Isaacs S.D., et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 2008, 68(12):1257-1262.
78. Zheng S.L., Sun J., Wiklund F., et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008, 358(9):910-919.
79. Lange E.M., Gillanders E.M., Davis C.C., et al. Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate 2003, 57(4):326-334.
80. Gillanders E.M., Xu J., Chang B.L., et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 2004, 96(16):1240-1247.
81. Ewing C.M., Ray A.M., Lange E.M., et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012, 366(2):141-149.
82. Breyer J.P., Avritt T.G., McReynolds K.M., et al. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2012, 21(8):1348-1353.
83. Akbari M.R., Trachtenberg J., Lee J., et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst 2012, 104(16):1260-1262.
84. Karlsson R., Aly M., Clements M., et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol 2014, 65(1):169-176.
85. Lin X., Qu L., Chen Z., et al. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 2013, 73(2):169-175.
86. Laitinen V.H., Wahlfors T., Saaristo L., et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2013, 22(3):452-460.
87. Xu J., Sun J., Kader A.K., et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009, 69(14):1565-1572.
88. Helfand B.T., Kan D., Modi P., et al. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination. Prostate 2011, 71(4):394-402.
89. Wang M., Liu F., Hsing A.W., et al. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case-control study in the ChinaPCa consortium. Carcinogenesis 2012, 33(2):356-360.
90. Chen M., Huang Y.C., Yang S., et al. Common variants at 8q24 are associated with prostate cancer risk in Taiwanese men. Prostate 2010, 70(5):502-507.
91. Helfand B.T., Loeb S., Kan D., et al. Number of prostate cancer risk alleles may identify possibly 'insignificant' disease. BJU Int 2010, 106(11):1602-1606.
92. Spitz M.R., Etzel C.J., Dong Q., et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) 2008, 1(4):250-254.
93. Barlow W.E., White E., Ballard-Barbash R., et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006, 98(17):1204-1214.
94. Gudmundsson J., Besenbacher S., Sulem P., et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010, 2(62):62ra92.
95. Aly M., Wiklund F., Xu J., et al. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol 2011, 60(1):21-28.
96. Odedina F.T., Akinremi T.O., Chinegwundoh F., et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 2009, 4(Suppl 1):S2.
97. Williams H., Powell I.J. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol 2009, 472:439-453.
98. Powell I.J., Banerjee M., Bianco F.J., et al. The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data. J Urol 2004, 171(4):1508-1512.
99. Ishak M.B., Giri V.N. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev 2011, 20(8):1599-1610.
100. Okobia M.N., Zmuda J.M., Ferrell R.E., et al. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 2011, 71(10):1054-1063.
101. Bensen J.T., Xu Z., Smith G.J., et al. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate 2013, 73(1):11-22.
102. Haiman C.A., Chen G.K., Blot W.J., et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 2011, 7(5):e1001387.
103. Haiman C.A., Chen G.K., Blot W.J., et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011, 43(6):570-573.
104. Xu Z., Bensen J.T., Smith G.J., et al. GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate 2011, 71(8):881-891.
105. Whitman E.J., Pomerantz M., Chen Y., et al. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev 2010, 19(1):1-8.
106. Hooker S., Hernandez W., Chen H., et al. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. Prostate 2010, 70(3):270-275.
107. Xu J., Kibel A.S., Hu J.J., et al. Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev 2009, 18(7):2145-2149.
108. Chang B.L., Spangler E., Gallagher S., et al. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 2011, 20(1):23-32.
109. Zeigler-Johnson C.M., Rennert H., Mittal R.D., et al. Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 2008, 15(3):4056-4064.
110. Djavan B., Eckersberger E., Finkelstein J., et al. Prostate-specific antigen testing and prostate cancer screening. Prim Care 2010, 37(3):441-459. vii.
111. Helfand B.T., Loeb S., Hu Q., et al. Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. J Urol 2013, 189(5):1697-1701.
112. Bansal A., Murray D.K., Wu J.T., et al. Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. J Clin Endocrinol Metab 2000, 85(3):1272-1276.
113. Pilia G., Chen W.M., Scuteri A., et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet 2006, 2(8):e132.
114. Loeb S. Germline sequence variants and prostate-specific antigen interpretation. Clin Chem 2011, 57(5):662-663.
115. Loeb S., Carter H.B., Walsh P.C., et al. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol 2009, 182(1):101-104. [discussion: 105].
116. Guy M., Kote-Jarai Z., Giles G.G., et al. Identification of new genetic risk factors for prostate cancer. Asian J Androl 2009, 11(1):49-55.
117. Nam R.K., Zhang W.W., Klotz L.H., et al. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res 2006, 12(21):6452-6458.
118. Lose F., Batra J., O'Mara T., et al. Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urol Oncol 2011, 31(5):635-643.
119. Pomerantz M.M., Werner L., Xie W., et al. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila) 2011, 4(5):719-728.
120. Kohli M., Rothberg P.G., Feng C., et al. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark 2010, 7(2):101-108.
121. Cheng I., Plummer S.J., Neslund-Dudas C., et al. Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 2010, 19(9):2124-2132.
122. Cramer S.D., Sun J., Zheng S.L., et al. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(9):2451-2457.
123. Pal P., Xi H., Sun G., et al. Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum Genet 2007, 122(3-4):251-259.
124. Lu X., Zhao W., Huang J., et al. Common variation in KLKB1 and essential hypertension risk: tagging-SNP haplotype analysis in a case-control study. Hum Genet 2007, 121(3-4):327-335.
125. Cramer S.D., Chang B.L., Rao A., et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 2003, 95(14):1044-1053.
126. Parikh H., Wang Z., Pettigrew K.A., et al. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum Genet 2011, 129(6):675-685.
127. Vickers A., Cronin A., Roobol M., et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010, 28(15):2493-2498.
128. Vickers A.J., Cronin A.M., Roobol M.J., et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010, 16(12):3232-3239.
129. Donin N, Loeb S, Cooper PR, et al. Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African-American men. BJU Int, in press.
130. Scardino P.T. Prostate cancer: improving PSA testing by adjusting for genetic background. Nat Rev Urol 2013, 10(4):190-192.
131. Kwon E.M., Salinas C.A., Kolb S., et al. Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2011, 20(5):923-933.
132. Camp N.J., Farnham J.M., Wong J., et al. Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study. Cancer Epidemiol Biomarkers Prev 2009, 18(4):1290-1294.
133. Lu L., Cancel-Tassin G., Valeri A., et al. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate 2012, 72(4):410-426.
134. Amin Al Olama A., Kote-Jarai Z., Schumacher F.R., et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 2013, 22(2):408-415.
135. Penney K.L., Pyne S., Schumacher F.R., et al. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2010, 19(11):2869-2876.
136. Pal P., Xi H., Guha S., et al. Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry. Prostate 2009, 69(14):1548-1556.
137. Gudmundsson J., Sulem P., Rafnar T., et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008, 40(3):281-283.
138. Duggan D., Zheng S.L., Knowlton M., et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007, 99(24):1836-1844.
139. FitzGerald L.M., Kwon E.M., Conomos M.P., et al. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011, 20(6):1196-1203.
140. Xu J., Zheng S.L., Isaacs S.D., et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A 2010, 107(5):2136-2140.
141. Ahn J., Kibel A.S., Park J.Y., et al. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res 2011, 17(5):1075-1081.
142. Xu J., Isaacs S.D., Sun J., et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 2008, 14(18):5819-5824.
143. Severi G., Hayes V.M., Padilla E.J., et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):610-612.
144. Sun J., Zheng S.L., Wiklund F., et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 2009, 69(1):10-15.
145. Sun J., Purcell L., Gao Z., et al. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate 2008, 68(7):691-697.
146. Ostrander E.A., Kwon E.M., Stanford J.L. Genetic susceptibility to aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(10):1761-1764.
147. Lin D.W., FitzGerald L.M., Fu R., et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 2011, 20(9):1928-1936.
148. Bailey-Wilson J.E., Childs E.J., Cropp C.D., et al. Analysis of Xq27-28 linkage in the International Consortium for Prostate Cancer Genetics (ICPCG) families. BMC Med Genet 2012, 13:46.
149. Kote-Jarai Z., Amin Al Olama A., Leongamornlert D., et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 2011, 129(6):687-694.
150. Reinhardt D., Helfand B.T., Cooper P.R., et al. Prostate cancer risk alleles are associated with prostate cancer tumor volume and prostate size. J Urol 2013, [Epub ahead of print].
151. Witte J.S., Goddard K.A., Conti D.V., et al. Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet 2000, 67(1):92-99.
152. Goddard K.A., Witte J.S., Suarez B.K., et al. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 2001, 68(5):1197-1206.
153. Neville P.J., Conti D.V., Paris P.L., et al. Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia 2002, 4(5):424-431.
154. Liu X., Cheng I., Plummer S.J., et al. Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. Prostate 2011, 71(7):682-689.
155. Johanneson B., McDonnell S.K., Karyadi D.M., et al. Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. Hum Mol Genet 2010, 19(19):3852-3862.
156. Camp N.J., Farnham J.M., Cannon Albright L.A. Genomic search for prostate cancer predisposition loci in Utah pedigrees. Prostate 2005, 65(4):365-374.
157. Schaid D.J., McDonnell S.K., Zarfas K.E., et al. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet 2006, 120(4):471-485.
158. Cicek M.S., Conti D.V., Curran A., et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004, 59(1):69-76.
159. Hayes V.M., Severi G., Southey M.C., et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006, 15(6):1223-1225.
160. Huang S.P., Huang C.Y., Wu W.J., et al. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006, 119(8):1902-1907.
161. Wright J.L., Neuhouser M.L., Lin D.W., et al. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate 2011, 71(5):498-506.
162. Langeberg W.J., Tahir S.A., Feng Z., et al. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 2010, 70(9):1020-1035.
163. Lubahn J., Berndt S.I., Jin C.H., et al. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate 2010, 70(6):646-653.
164. Fradet V., Cheng I., Casey G., et al. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009, 15(7):2559-2566.
165. Mikhak B., Hunter D.J., Spiegelman D., et al. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 2008, 29(12):2335-2340.
166. Stevens V.L., Rodriguez C., Talbot J.T., et al. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Prostate 2008, 68(12):1336-1340.
167. Neslund-Dudas C., Bock C.H., Monaghan K., et al. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 2007, 67(15):1654-1663.
168. Casey G., Neville P.J., Liu X., et al. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 2006, 15(5):735-741.
169. Vickers A.J., Gupta A., Savage C.J., et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011, 20(2):255-261.
170. Batra J., O'Mara T., Patnala R., et al. Genetic polymorphisms in the human tissue kallikrein (KLK) locus and their implication in various malignant and non-malignant diseases. Biol Chem 2012, 393(12):1365-1390.
171. Penney K.L., Schumacher F.R., Kraft P., et al. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis 2011, 32(6):853-859.
172. Eeles R.A., Kote-Jarai Z., Giles G.G., et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40(3):316-321.
173. Lindstrom S., Schumacher F., Siddiq A., et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3. PLoS One 2011, 6(2):e17142.
174. Stott-Miller M., Karyadi D.M., Smith T., et al. HOXB13 mutations in a population-based, case-control study of prostate cancer. Prostate 2013, 73(6):634-641.
175. Xu J., Lange E.M., Lu L., et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2013, 132(1):5-14.
176. Cooperberg M.R., Simko J.P., Cowan J.E., et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013, 31(11):1428-1434.
177. Cooperberg MR, Simko JP, Falzarano S, et al. Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance. AUA 2013 Annual Meeting 2013 (Abstract #2131). San Diego, May 8, 2013.
178. Hindorff L.A., Gillanders E.M., Manolio T.A. Genetic architecture of cancer and other complex diseases: lessons learned and future directions. Carcinogenesis 2011, 32(7):945-954.
179. Berger M.F., Lawrence M.S., Demichelis F., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470(7333):214-220.
180. Lindberg J., Klevebring D., Liu W., et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol 2013, 63(2):347-353.
181. El Melegy N.T., Aboulella H.A., Abul-Fadl A.M., et al. Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer. Br J Biomed Sci 2010, 67(3):109-112.
182. Potter S.R., Reckwitz T., Partin A.W. The use of percent free PSA for early detection of prostate cancer. J Androl 1999, 20(4):449-453.
183. Catalona W.J., Partin A.W., Slawin K.M., et al. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 2000, 55(3):372-376.
184. Mikolajczyk S.D., Catalona W.J., Evans C.L., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004, 50(6):1017-1025.
185. Sokoll L.J., Chan D.W., Mikolajczyk S.D., et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 2003, 61(2):274-276.
186. Perdona S., Bruzzese D., Ferro M., et al. Prostate health index (PHI) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013, 73(3):227-235.
187. Houlgatte A., Vincendeau S., Desfemmes F., et al. Use of [-2] pro PSA and PHI index for early detection of prostate cancer: a prospective of 452 patients. Prog Urol 2012, 22(5):279-283. [in French].
188. Nichol M.B., Wu J., Huang J., et al. Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU Int 2012, 110(3):353-362.
189. Jansen F.H., van Schaik R.H., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57(6):921-927.
190. Lazzeri M., Haese A., Abrate A., et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013, 112(3):313-321.
191. Stephan C., Vincendeau S., Houlgatte A., et al. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2013, 59(1):306-314.
192. Loeb S., Sokoll L.J., Broyles D.L., et al. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol 2013, 189(5):1702-1706.
193. Hessels D., Klein Gunnewiek J.M., van Oort I., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003, 44(1):8-15. [discussion: 15-6].
194. de Kok J.B., Verhaegh G.W., Roelofs R.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002, 62(9):2695-2698.
195. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179(4):1587-1592.
196. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008, 179(5):1804-1809. [discussion: 1809-10].
197. Lin D.W., Newcomb L.F., Brown E.C., et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013, 19(9):2442-2450.
198. Whitman E.J., Groskopf J., Ali A., et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008, 180(5):1975-1978. [discussion 1978-9].
199. Stephan C., Jung K., Semjonow A., et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013, 59(1):280-288.
200. Liu W., Xie C.C., Zhu Y., et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 2008, 10(8):897-907.
201. Sun J., Liu W., Adams T.S., et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007, 67(7):692-700.
202. Taylor B.S., Schultz N., Hieronymus H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18(1):11-22.
203. Nickerson M.L., Im K.M., Misner K.J., et al. Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat 2013, 34(9):1231-1241.
204. Liu W., Xie C.C., Thomas C.Y., et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer 2013, 119(13):2405-2412.
205. Dean M., Lou H. Genetics and genomics of prostate cancer. Asian J Androl 2013, 15(3):309-313.
206. Zafarana G., Ishkanian A.S., Malloff C.A., et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 2012, 118(16):4053-4062.
207. Cheng I., Levin A.M., Tai Y.C., et al. Copy number alterations in prostate tumors and disease aggressiveness. Genes Chromosomes Cancer 2012, 51(1):66-76.
208. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008, 8(7):497-511.
209. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648.
210. Palanisamy N., Ateeq B., Kalyana-Sundaram S., et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010, 16(7):793-798.
211. Kollermann J., Albrecht H., Schlomm T., et al. Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Oncol Lett 2010, 1(4):729-732.
212. Tomlins S.A., Bjartell A., Chinnaiyan A.M., et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009, 56(2):275-286.
213. Tomlins S.A., Aubin S.M., Siddiqui J., et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011, 3(94):94ra72.
214. Barbieri C.E., Baca S.C., Lawrence M.S., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012, 44(6):685-689.
215. Grasso C.S., Wu Y.M., Robinson D.R., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487(7406):239-243.
216. Eeles R.A., Kote-Jarai Z., Al Olama A.A., et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009, 41(10):1116-1121.
217. Gudmundsson J., Sulem P., Manolescu A., et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007, 39(5):631-637.
218. Gudmundsson J., Sulem P., Steinthorsdottir V., et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007, 39(8):977-983.
219. Kote-Jarai Z., Olama A.A., Giles G.G., et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011, 43(8):785-791.
220. Schumacher F.R., Berndt S.I., Siddiq A., et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011, 20(19):3867-3875.
221. Thomas G., Jacobs K.B., Yeager M., et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008, 40(3):310-315.
222. Cuzick J., Swanson G.P., Fisher G., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011, 12(3):245-255.
223. Cuzick J., Berney D.M., Fisher G., et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012, 106(6):1095-1099.
224. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999, 59(23):5975-5979.
225. de la Taille A. Progensa PCA3 test for prostate cancer detection. Expert Rev Mol Diagn 2007, 7(5):491-497.
226. Kirby R. PCA3 improves diagnosis of prostate cancer. Practitioner 2007, 251(1690):18. 21, 23.
227. Stewart G.D., Van Neste L., Delvenne P., et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol 2013, 189(3):1110-1116.
228. Trock B.J., Brotzman M.J., Mangold L.A., et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 2012, 110(1):56-62.
229. Robinson K., Creed J., Reguly B., et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis 2010, 13(2):126-131.
230. Badani K., Thompson D.J., Buerki C., et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 2013, 4(4):600-609.